Product Description
trial name (Sourced from: )
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06144671 |
GT-CD-CHN-201-01 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-09-13 |
49% |
2023-11-27 |
Primary Endpoints|Treatments |
NCT05430360 |
GT201 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-05-01 |
50% |
2022-06-25 |
Primary Endpoints |
NCT05729399 |
GRIT-CD-MED-CHN-001 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-05-01 |
12% |
2025-02-08 |
Patient Enrollment|Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/04/2025 |
News Article |
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801 |
|
05/29/2025 |
News Article |
Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting |
|
05/12/2025 |
News Article |
Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting |
|
10/31/2023 |
News Article |
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update |